Table 3.

Effects of Tat and morphine on cytokine concentrations in the striatum of Tat transgenic mice that are not presented in Figs. 5 and 6

Striatal cytokines	Genotype	Repeated saline	Repeated morphine	Genotype effect		drug effect		Genotype x drug
pg/mL		mean ± SEM	mean ± SEM	F1, 19	p	F1, 19	p	F1, 19	p
Proinflammatory Cytokines
IL-2	Tat(−)	10.7 ± 0.61	10.7 ± 0.18	< 1.0	0.59	< 1.0	0.48	< 1.0	0.50
	Tat(+)	10.6 ± 0.33	11.2 ± 0.12
IL-6	Tat(−)	2.5 ± 0.08	3.2 ± 0.13	1.6	0.22	33.0	< 0.01	1.7	0.20
	Tat(+)	2.5 ± 0.08	2.9 ± 0.13
IFN-γ	Tat(−)	24.3 ± 0.63	24.9 ± 0.26	3.3	0.08	1.9	0.18	< 1.0	0.60
	Tat(+)	22.6 ± 0.46	24.0 ± 1.40
TNF-α	Tat(−)	45.1 ± 1.33	48.3 ± 1.58	< 1.0	0.87	2.9	0.11	< 1.0	0.68
	Tat(+)	44.4 ± 1.47	49.9 ± 5.14
Anti-Inflammatory Cytokines
IL-5	Tat(−)	2.2 ± 0.15	2.8 ± 0.09	1.7	0.20	26.0	< 0.01	< 1.0	0.99
	Tat(+)	2.0 ± 0.08	2.7 ± 0.20
IL-13	Tat(−)	36.9 ± 1.79	48.1 ± 0.99	3.4	0.08	39.6	< 0.01	< 1.0	0.54
	Tat(+)	31.9 ± 0.93	45.7 ± 3.73
Chemokines
CCL2	Tat(−)	42.2 ± 1.36	42.3 ± 1.08	13.6	< 0.01	< 1.0	0.60	< 1.0	0.60
	Tat(+)	38.4 ± 1.01	37.1 ± 1.38
CCL3	Tat(−)	8.3 ± 0.82	10.5 ± 1.08	< 1.0	0.66	3.2	0.09	< 1.0	0.45
	Tat(+)	8.6 ± 0.63	9.5 ± 0.73
CCL4	Tat(−)	48.8 ± 0.42	47.8 ± 0.84	18.4	< 0.01	3.4	0.08	< 1.0	0.61
	Tat(+)	46.0 ± 0.93	44.2 ± 0.70
CCL11	Tat(−)	99.9 ± 1.77	96.6 ± 1.24	2.2	0.15	1.3	0.27	< 1.0	0.85
	Tat(+)	95.5 ± 3.53	91.0 ± 6.01

Cytokine concentrations in the striatum of repeated (8-day) saline- or morphine-treated Tat(−) and Tat(+) mice. Data are expressed as mean ± SEM in pg/mL. Samples were loaded at 900 μg/mL total protein. Two-way ANOVAs for each CNS region were conducted with genotype and drug as between-subjects factors. F values and p values are presented from ANOVA results. Bolded values denote significant differences at α = 0.05; n = 5–6 mice per group. Additional cytokines and chemokines are represented in Figs. 5 and 6